Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE.
ACEON vs QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Quinapril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion; hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
Initial: 10/12.5 mg (quinapril/hydrochlorothiazide) orally once daily. Titrate based on response to a maximum of 40/25 mg once daily.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Quinaprilat terminal half-life ~25 hours (effective half-life ~12 hours); hydrochlorothiazide ~6-15 hours (increased in renal impairment).
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Renal excretion of quinaprilat (active metabolite) ~50-60% unchanged; hydrochlorothiazide ~70% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor